Business
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer activity expands potential therapeutic reach of SIL204 GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for
About this update from Silexion Therapeutics Corp
[{"type":"image","alt":"Silexion Therapeutics Corp","displaySize":"","headline":null,"caption":"Silexion Therapeutics Corp","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/0e108fa5d2c179a927ea7dc4257aea29"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dEbifqbuIRrs3yctodIWKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0e108fa5d2c179a927ea7dc4257aea29","width":300,"height":116}},"lazy":false},{"type":"text","content":"New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations","length":169,"tagName":"p"},{"type":"text","content":"Company Reports first evidence of gastric cancer activity expands potential therapeutic reach of SIL204","length":103,"tagName":"p"},{"type":"text","content":"GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that SIL204 has demonstrated activity against eleven human cell lines originating from 5 different organ cancer sites, each with a specific KRAS mutation. High inhibition was achieved with inhibition rates ranging between 83.5% to 99.7%, including the Company's first data in gastric cancer and expanded validation in colorectal cancer.","length":641,"tagName":"p"},{"type":"text","content":"The new preclinical CTG (Cell Titer-Glo) assay results confirm SIL204's activity in human tumor cell lines for clinically significant mutations such as G12R which is 17%1 of pancreatic cancer and has been difficult to inhibit by the small molecule KRAS inhibitors. This new data with the previously reported in silico finding that SIL204 is specific for KRAS but not the other RAS isozymes provide first human cell line data for validating SIL204's therapeutic potential as a comprehensive pan-KRAS isoform selective inhibitor.","length":541,"tagName":"p"},{"type":"text","content":""These results validate SIL204 as a true pan-KRAS therapeutic candidate, now demonstrating high activity against a range of different KRAS muta...